 |
 |

Childhood AdrenoleukodystrophyFailure of Intensive Immunosuppression to Arrest Neurologic Progression
Sakkubai Naidu, MB, BS;
Michael J. Bresnan, MD;
Diane Griffin, MD;
Susan O'Toole, RN, MS;
Hugo W. Moser, MD
Arch Neurol. 1988;45(8):846-848.
Abstract
Cyclophosphamide in a dosage of 350 to 700 mg/m2/d was administered for five to 11 days to four patients with childhood adrenoleukodystrophy (ALD) and to one patient with the adult cerebral form of the disease. The rate of neurologic progression in the four patients with childhood ALD did not differ from that of 167 untreated patients with childhood ALD surveyed previously.
Author Affiliations
From the John F. Kennedy Institute (Drs Naidu and Moser and Ms O'Toole) and Departments of Neurology and Pediatrics (Drs Naidu, Griffin, and Moser), The Johns Hopkins University, Baltimore; and the Department of Neurology, Harvard University and the Children's Medical Center (Dr Bresnan), Boston.
Footnotes
Accepted for publication Feb 22, 1988.
Deceased.
Reprint requests to John F. Kennedy Institute, 707 N Broadway, Baltimore, MD 21205 (Dr Naidu).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Adrenomyeloneuropathy as a cause of primary adrenal insufficiency and spastic paraparesis
Spurek et al.
CMAJ 2004;171:1073-1077.
ABSTRACT
| FULL TEXT
Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil"
van Geel et al.
J. Neurol. Neurosurg. Psychiatry 1999;67:290-299.
ABSTRACT
| FULL TEXT
A mouse model for X-linked adrenoleukodystrophy
Lu et al.
Proc. Natl. Acad. Sci. USA 1997;94:9366-9371.
ABSTRACT
| FULL TEXT
X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy
van Geel et al.
J. Neurol. Neurosurg. Psychiatry 1997;63:4-14.
ABSTRACT
| FULL TEXT
|